Larotrectinib (Vitrakvi ®)

Since April 1, 2021, there is a reimbursement of Larotrectinib (Vitrakvi ®) by the RIZIV/INAMI. Larotrectinib is used to treat adult and pediatric patients with locally advanced or metastatic solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion which cannot be treated satisfactorily with the available treatment options.

The target group is defined as follows:

  • patients with Belgian health Insurance
  • with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation
  • of which the tumor is locally advanced or metastatic, or the surgical resection is likely to result in severe morbidity
  • that do not have satisfactory alternative treatments
  • after approval by a multidisciplinary oncology consultation (MOC)


The reimbursement can be granted based on an electronic application via the eHealth platform.


This reimbursement is linked to a mandatory registration of tumor and outcome-specific variables via the Belgian Cancer Registry. There are 3 registration time points:

  • At the latest 1 month after the eHealth application for the Larotrectinib treatment: registration form
  • At the latest 6 months after the end of the Larotrectinib treatment: registration form
  • If the patient is still being treated with Larotrectinib on September 15, 2023: registration form

Registrations can be submitted from 01/04/2021 via the Web Based Cancer Registration (WBCR) application of the Belgian Cancer Registry (project module "Larotrectinib"). More information about the usage of this application is available in the WBCR manual.


If you would like more information about the Larotrectinib registration project, please contact us via mailto:larotrectinib@kankerregister.orgor via 02/250 10 10.